Ann Oncol 32 (8): 994-1004, 2021.[PUBMED Abstract] Bardia A, Mayer IA, Vahdat LT, et al.: Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med 380 (8): 741-751, 2019.[PUBMED Abstract] Bardia A, Hurvitz SA, Tolaney SM, et al.: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med 384 (16): 1529-1541, 2021.[PUBMED Abstract] Winer EP, Lipatov O, Im SA, et al.: Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Lancet Oncol 22 (4): 499-511, 2021.[PUBMED Abstract] Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy.